Tests alpibectir with ethionamide for newly diagnosed lung tuberculosis
Tests alpibectir and ethionamide, alone or with standard tuberculosis drugs, in adults.
Key facts
- Who runs it
- TASK Applied Science
- Where
- Cape Town, South AfricaSee the site
- Trial code
- Registry title
- A Study of the Early Effects, Safety, and Acceptability of Oral Alpibectir in Combination With Ethionamide
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 60 people, planned
- Started
- 3 Mar 2025
- Planned end
- 30 Mar 2026
- Type of study
- Interventional, 5 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Alpibectir 45 mg once daily (OD) plus Ethionamide 125 mg OD
- Alpibectir 45 mg OD plus Ethionamide 250 mg OD
- Isoniazid, rifampicin, pyrazinamide and ethambutol fixed dose combination, weight based
- Alpibectir 45 mg OD plus Ethionamide 250 mg OD plus Rifampicin 10 mg/kg OD plus Ethambutol 20 mg/kg OD plus Pyrazinamide 25 mg/kg OD
- Record updated
- 7 March 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with newly diagnosed lung tuberculosis (TB) that still responds to isoniazid and rifampicin, and who have not yet had treatment for this episode of TB.
- Age
- 18 to 65 years
- Sex
- Men and women
- Disease stage
- Newly diagnosed pulmonary TB, not yet treated for this episode. Susceptible to rifampicin and isoniazid on molecular testing. GeneXpert positive with a medium or high result. Chest X-ray consistent with TB. Able to produce enough sputum (about 10 ml or more).
- Earlier treatment
- No treatment for this episode of TB with any drug active against TB. No other trial drug within 8 weeks before screening.
- Biomarker or test result
- Rifampicin- and isoniazid-susceptible TB on molecular testing. GeneXpert positive with a medium or high quantitative result.
Main reasons for not taking part
- Pregnant or breast-feeding women, or people planning to conceive during the trial
- Hepatitis B or hepatitis C positive
- HIV positive with CD4 below 250 cells/mm3, or on an ART regimen not allowed by the trial
- History of epilepsy, seizures or hypothyroidism, or cirrhosis or unstable liver disease
- QTcF above 450 ms at baseline, or TB outside the chest
The registry criteria, word for word
Show all 29 criteriaShow less
Who can take part
- Provide written, informed consent prior to all trial-related procedures and willing to adhere to all required study procedures and restrictions for the duration of the trial
- Male or female, aged between 18 and 65 years, inclusive
- Body weight (in light clothing and with no shoes) between 40 and 90 kg, inclusive
- Newly diagnosed and untreated for this episode of pulmonary TB
- Rifampicin- and isoniazid susceptible pulmonary TB as determined by molecular testing (GeneXpert XDR or Genotype MTBDRplus for INH)
- A chest X-ray taken during the screening period or up to 2 weeks before screening which, in the opinion of the investigator, is consistent with TB
- GeneXpert positive with a quantitative readout of medium or high
- Ability to produce an adequate volume of sputum as estimated from an overnight sputum collection sample (estimated 10 ml or more)
- Be of non-childbearing potential or of childbearing potential using effective methods of birth control, as defined in section 5.2 and in Appendix 1; Female Participants
- For WOCBP who are not already receiving contraception per Appendix 1 requirements, agree to receive injectable or other contraceptive methods (per Appendix 1), to be given during screening, and at least 1 day prior to first dose of IMP; Male Participants
- Agree to ALL of the following during the study intervention period and for at least 90 days, after the last dose of study intervention:; Refrain from donating fresh unwashed semen; Agree to use a male condom when engaging in any activity that allows for passage of ejaculate to another person
Who cannot take part
- Alcohol or drug abuse, that in the opinion of the investigator, is sufficient to compromise the safety or cooperation of the participant
- Participation in other clinical studies with investigational agents within 8 weeks prior to screening
- Treatment received for this episode of TB with any drug active against M. tb (including but not limited to isoniazid, ethambutol, cycloserine, fluoroquinolones, rifamycins, aminoglycosides, nitroimidazoles, bedaquiline, oxazolidinones, para-amino salicylic acid, pyrazinamide, thioacetazone, thioamides)
- Treatment with immunosuppressive medications such as TNF-alpha inhibitors within 2 weeks prior to screening, or systemic corticosteroids for more than 7 days within 2 weeks prior to screening
- Evidence of clinically significant conditions or findings, other than TB, that might compromise safety or the interpretation of trial endpoints, per discretion of the investigator
- Poor general condition where any delay in treatment cannot be tolerated per discretion of the investigator
- History of epilepsy, seizures or other neuropsychiatric disorders that might compromise safety or the interpretation of trial endpoints, per discretion of the investigator
- Cirrhosis or current unstable liver or biliary disease per investigator assessment defined by the presence of ascites, encephalopathy, coagulopathy, hypoalbuminaemia, oesophageal or gastric varices, persistent jaundice (with the exception of Gilbert's syndrome or asymptomatic gallstones)
- History of hypothyroidism
- History of allergy to any of the trial IMP as confirmed by the clinical judgement of the investigator
- HIV positive AND:; CD4 < 250cells/mm3; On other ART regimen not listed below or, if not on ART they are not willing to wait to start treatment until completion of study regimen; Note: ART regimens permitted is limited to the following in line with local guidelines for 1st line ART:; NRTIs selected from: Emtricitabine, Lamivudine, Tenofovir; PLUS Dolutegravir 50 mg daily, or 50 mg twice daily if randomized to a rifampicin containing arm; Participants established on ART (2 NRTIs and dolutegravir) for more than 30 days at start of screening are eligible for participation; As the drug-drug interaction potential of ART has not been fully investigated with the IMP, NNRTIs (efavirenz, nevirapine) and other protease inhibitors will not be permitted in this study
- Presence of hepatitis B surface antigen (HBsAg+)
- Positive hepatitis C antibody test result (HCV IgG+)
- Unavoidable treatment with prohibited concomitant medications (see section 5.3.2) anticipated during administration of IMP; Laboratory Safety Testing
- Participants with the following toxicities at screening as defined by the enhanced CTCAE toxicity table:; creatinine >1.5 times upper limit of normal (ULN); haemoglobin <8.0 g/dL; platelets <50x109 cells/L; serum potassium <3.0 mmol/L; alanine aminotransferase (ALT) ≥5 x ULN; total bilirubin >1.5 x ULN; Participants with Gilbert's syndrome can be included with total bilirubin >1.5 x ULN as long as direct bilirubin is ≤1.5xULN; Total white cell count <1.5 cells/L; Thyroid Stimulating Hormone > ULN; Glucose < 3.5 mmol/L
- QTcF of >450 ms at baseline
- Clinically significant evidence of extra-thoracic TB, as judged by the investigator
- Female participant who is pregnant, breast-feeding, or planning to conceive a child within the anticipated period of trial participation and for at least 90 days after the last dose of study intervention. Male participant planning to conceive a child for at least 90 days, after the last dose of study intervention in the trial; Treatment History
The main criteria, as questions
These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Are you between 18 and 65 years old?
This trial is currently available in South Africa.
- TASKCape Town, South AfricaContact: Gifty Okyere-Manu, MBChBTaking people
About the trial
What the trial wants to find out
A multi-centre, randomized, open-label clinical trial. All treatments will be administered orally (PO) on days 1-14.
Read full original descriptionShow less
15 participants will be recruited into each treatment arm in two sequential cohorts. Each cohort will have participants enrolled onto the experimental regimen(s) or the standard of care (SOC; HRZE) control arm.
• Cohort 1 aims to generate safety data for a higher dose of alpibectir plus ethionamide 125 mg and 250 mg (arm 1: A45E125 and arm2: A45E250).
Once 5 participants have enrolled into arms 1 and 2 each, and completed 14 days of treatment, an interim safety review will be conducted to determine whether the study can advance to cohort 2.
• Cohort 2 will investigate safety of alpibectir and ethionamide (A45E250) in combination with rifampicin, pyrazinamide and ethambutol (A45E250RZE).
Participants on HRZE will serve as control for the EBA quantitative mycobacteriology in each cohort, and additionally as a safety benchmark for the A45E250RZE arm. The study is not statistically powered to make between arm comparisons of activity or safety. The treatment will not be blinded but the mycobacteriology laboratory staff performing the endpoint assays will remain blinded until analysis of the EBA results.
The 5 groups in the trial
- Cohort 1 Arm 1 (A45E125)Treatment being tested
Alpibectir 45 mg once daily (OD) plus Ethionamide 125 mg OD
Treatment: Alpibectir 45 mg once daily (OD) plus Ethionamide 125 mg OD
- Cohort 1 Arm 2 (A45E250)Treatment being tested
Alpibectir 45 mg OD plus Ethionamide 250 mg OD
Treatment: Alpibectir 45 mg OD plus Ethionamide 250 mg OD
- Cohort 1 Arm 3 (HRZE)Existing treatment, for comparison
Isoniazid, rifampicin, pyrazinamide and ethambutol fixed dose combination, weight based
Treatment: Isoniazid, rifampicin, pyrazinamide and ethambutol fixed dose combination, weight based
- Cohort 2 Arm 3 (HRZE)Existing treatment, for comparison
Isoniazid, rifampicin, pyrazinamide and ethambutol fixed dose combination, weight based
Treatment: Isoniazid, rifampicin, pyrazinamide and ethambutol fixed dose combination, weight based
- Cohort 2 Arm 4 (A45E250RZE)Treatment being tested
Alpibectir 45 mg OD plus Ethionamide 250 mg OD plus Rifampicin 10 mg/kg OD plus Ethambutol 20 mg/kg OD plus Pyrazinamide 25 mg/kg OD
Treatment: Alpibectir 45 mg OD plus Ethionamide 250 mg OD plus Rifampicin 10 mg/kg OD plus Ethambutol 20 mg/kg OD plus Pyrazinamide 25 mg/kg OD
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Phase 2 Randomized, Open-label Trial to Evaluate the Early Bactericidal Activity, Safety, Tolerability, and Dose-Response of Oral Alpibectir in Combination With Ethionamide, and With Ethionamide, Rifampicin, Pyrazinamide, and Ethambutol in Adults With Newly Diagnosed, Drug-Susceptible Pulmonary Tuberculosis
- Plain-language title
- Tests alpibectir with ethionamide for newly diagnosed lung tuberculosisGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Criteria questions
- Built from NCT06748937, who can take part
- Record updated
- 7 March 2025